ASX Biotech Bets Big on Bitcoin Treasury Move to Dodge Financial Collapse

Desperate times call for decentralized measures—one Australian biotech firm just swapped its cash reserves for BTC.

The Hail Mary Playbook

Facing volatile markets and dwindling funding, the ASX-listed company pivoted to a corporate Bitcoin strategy straight out of MicroStrategy’s playbook. No IPO exits, no VC lifelines—just pure orange-pilled conviction.

Wall Street Rolls Its Eyes

Analysts predict either genius or recklessness as the firm stakes its runway on crypto’s notorious volatility. ‘Because nothing says stability like an asset that can swing 20% before lunch,’ quipped one fund manager.

The gamble highlights a growing trend: cash-strapped firms treating Bitcoin not as inflation hedge, but as existential lottery ticket. Will they moon or get rekt? Stay tuned.